P/E at 36.04 vs Industry's 36.64: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Close Match to Industry Norms

The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.04, marginally below the Pharmaceuticals & Biotechnology industry average of 36.64. This near equivalence suggests that the market is pricing the stock in line with sector expectations, neither assigning a significant premium nor discount. Such valuation alignment often reflects a consensus on the company’s earnings growth prospects and risk profile relative to its peers. However, the subtle discount could indicate cautious sentiment given recent performance trends — previously rated Buy, what is Sun Pharma’s current rating? The P/E metric alone, while important, must be considered alongside other performance indicators to fully understand the stock’s positioning.

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a complex momentum profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 16.42% gain, significantly outperforming the Sensex’s decline of 5.45%. This strong annual performance is further underscored by impressive longer-term returns of 67.80% over three years and 150.02% over five years, both well ahead of the Sensex’s respective 19.17% and 39.89% gains.

Yet, the recent short-term data signals a slowdown. The stock has declined by 2.05% over the past week and 2.72% over the last month, underperforming the Sensex’s more modest falls of 0.87% and 0.40% respectively. Even over three months, the stock’s 1.20% gain lags behind the Sensex’s 2.76%. This divergence between strong medium-to-long-term returns and weaker short-term momentum raises questions about the sustainability of recent gains — is this a temporary pause or a sign of deeper challenges?

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is equally nuanced. The stock price currently trades above its 50-day, 100-day, and 200-day moving averages, indicating a solid base and longer-term support. However, it remains below the 5-day and 20-day moving averages, suggesting recent short-term weakness or consolidation. This configuration often points to a stock in a recovery phase within a broader sideways or mildly bearish trend — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The interplay between short and long-term moving averages will be critical to watch for confirming trend direction.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently, with 34 stocks having declared results so far. Of these, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution suggests a sector grappling with uneven earnings momentum, which may be influencing investor sentiment towards Sun Pharmaceutical Industries Ltd. The stock’s performance relative to this backdrop is notable, as it has managed to sustain positive returns over the year despite the sector’s varied results — how does Sun Pharma’s performance stack up against its sector peers?

Rating Reassessment: From Buy to Hold

MarketsMOJO’s previous rating for Sun Pharmaceutical Industries Ltd was Buy, reflecting confidence in the company’s prospects. However, as of 17 Aug 2026, this rating has been updated to Hold. This change aligns with the data-driven insights of a valuation close to industry norms, combined with the recent short-term underperformance and mixed technical signals. The reassessment underscores the importance of balancing strong historical returns with caution over near-term momentum — should investors in Sun Pharma hold, buy more, or reconsider?

Market Capitalisation and Trading Activity

Sun Pharmaceutical Industries Ltd is a large-cap stock with a market capitalisation of ₹4,56,593.44 crores. On 20 Aug 2026, the stock opened at ₹1,910 and traded inline with the sector, registering a modest gain of 0.26%. It has been on a two-day consecutive gain streak, accumulating a 1.79% rise during this period. This recent uptick, however, contrasts with the stock’s position below the 5-day and 20-day moving averages, indicating short-term resistance despite longer-term support.

Long-Term Returns: A Strong Track Record

Over the past decade, Sun Pharmaceutical Industries Ltd has delivered a 143.13% return, slightly trailing the Sensex’s 175.67% over the same period. Nonetheless, the stock’s five-year return of 150.02% significantly outpaces the Sensex’s 39.89%, highlighting periods of strong outperformance. This long-term growth trajectory is a key factor in the stock’s valuation and rating considerations.

Conclusion: Data Reflects a Balanced Outlook

The comprehensive data on Sun Pharmaceutical Industries Ltd reveals a stock trading at a valuation closely aligned with its industry peers, supported by solid long-term returns but facing recent short-term momentum challenges. The moving average configuration suggests a stock in a tentative recovery phase, while sector results remain mixed. The rating update from Buy to Hold reflects this balanced view, emphasising the need to weigh strong historical performance against current technical and momentum signals — what does the current rating mean for investors in Sun Pharma?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today